Team

Principals

Stephen Einhorn has participated in over 200 business sales and purchases as the founder and leader of Einhorn Associates. Mr. Einhorn has extensive experience in business valuation, acquisition searches, management buy-outs, and sales of privately-held businesses. He has worked on investments and transactions for over 30 years. During his career, Mr. Einhorn has published numerous articles relating to mergers and acquisitions and has been a speaker at BIO and other conferences. He has served as Chairman of the Entrepreneurial Committee of Cornell University’s Technology Transfer Committee. Mr. Einhorn earned an MS in chemical engineering from Brooklyn Polytechnic Institute, a BA in chemistry from Cornell, and attended Wharton Graduate School.

Daniel Einhorn focuses on new client development, syndicating investment for portfolio companies, financial analysis, strategic planning, and market research. His education includes an MBA in finance from the Cox business school at SMU, as well as a BS from Cornell University.

Alvin Vitangcol has 18 years of experience in venture capital and investment banking transactions. Mr. Vitangcol currently serves on the board for CMF’s investments in CytoPherx and OPS Solutions, and also served as a board director for Sierra Oncology (NASDAQ: SRRA) [fka ProNAi Therapeutics (NASDAQ: DNAI)] and a board observer for PrevaCept Infection Control (fka Great Lakes Pharmaceuticals). Previously as part of Einhorn Associates, he was the primary analyst for a number of M&A transactions and private placements, including the financing of Fulcrum Pharmaceuticals, which merged with Ception Therapeutics, and was subsequently acquired by Cephalon for $350 million with additional potential milestone payments. Mr. Vitangcol’s education includes an MS in Management (emphasis in eBusiness) with honors from the University of Wisconsin - Milwaukee, a BS in Sociology with honors from Andrews University, and a diverse educational background including minors in chemistry, math, and computer science.

Eli Blee-Goldman co-leads sourcing and due diligence. He focuses on all aspects of evaluation for advanced manufacturing and B2B portfolio companies and statistical analysis for the Fund’s healthcare investments. For Capital Midwest Fund II, he co-led due diligence for $20 million of investments, provided a variety of value-adding services for portfolio companies (including gaining national press and market research/financial analysis), and developed internal analyses to improve the Fund’s performance. He graduated magna cum laude from Beloit College with a BA in Economics and Modern Languages and a minor in Mathematics.

Support

Jacky Christiansen has over 25 years of experience with preparing financial analysis and valuations.

Katy Almond coordinates meetings and travel arrangements, and also assists with investor relations.